Cell Therapeutics To Launch First Commercial Product Trisenox With 16 Reps
Executive Summary
Cell Therapeutics will launch its first commercial product Trisenox for treatment of acute promyelocytic leukemia with an internal oncology sales force of 16 reps, CTI CEO James Bianco, MD, told a Sept. 27 conference call.
You may also be interested in...
Celgene, Agios Ready For Enasidenib Launch After Early Approval
Idhifa is the first treatment for AML patients with IDH2 mutations. The drug will be co-commercialized by Celgene and Agios under their 2010 collaboration and is the latter's first regulatory approval.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials